LONDON – Heptares Ltd. announced a four-year collaboration with AstraZeneca plc worth a potential $186 million, plus funding for research and development. That is the third deal this year around Heptares' stabilized G-protein coupled receptor (GPCR) platform and the first in which the technology will be used for antibody discovery. (BioWorld International)

LONDON – GenKyoTex SA raised CHF18 million (US$20.4 million) in a Series C round, enabling it to take the lead product to the point where it is ready to deliver proof of concept for the company's NOX enzyme inhibition technology. (BioWorld International)